Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
NCT06470243· Phase 3· SWOG Cancer Research Network· Source
Contact: Paul Corn (principal investigator)
Recruiting
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387· Phase 3· SWOG Cancer Research Network· Source
Contact: Jing Christine Ye (principal investigator)
Active, not recruiting
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source
Recruiting
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT04606446· Phase 2· Pfizer· Source
Active, not recruiting
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
NCT04155034· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· Phase 2/3· NRG Oncology· Source
Active, not recruiting
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
NCT03987386· Phase 3· M.D. Anderson Cancer Center· Source
Recruiting
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
NCT04169542· M.D. Anderson Cancer Center· Source
Contact: Richard A. Ehlers
Active, not recruiting
Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer
NCT03697148· ECOG-ACRIN Cancer Research Group· Source
Recruiting
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025· Phase 3· SWOG Cancer Research Network· Source
Contact: Brian F. Chapin (principal investigator)
Active, not recruiting
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
NCT03419234· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
NCT03391869· Phase 3· M.D. Anderson Cancer Center· Source
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02659241· Early phase 1· M.D. Anderson Cancer Center· Source
Active, not recruiting
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
NCT02276443· M.D. Anderson Cancer Center· Source
Active, not recruiting
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
NCT02397083· Phase 2· M.D. Anderson Cancer Center· Source
Active, not recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer
NCT01893307· Phase 3· M.D. Anderson Cancer Center· Source
Active, not recruiting
Young-Onset Colorectal Cancer
NCT02863107· M.D. Anderson Cancer Center· Source
Active, not recruiting
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
NCT01220583· Phase 2· Radiation Therapy Oncology Group· Source
Active, not recruiting
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851· Phase 3· National Cancer Institute (NCI)· Source